Bepirovirsen and the Pursuit of a Functional Cure for Hepatitis B

Bepirovirsen achieves functional cure in 19% of specific HBV patient populations

Bepirovirsen has demonstrated the ability to "functionally cure" approximately 19% of patients with Hepatitis B virus (HBV) infections. This result has been independently replicated across a study population of over 1,800 patients. However, the efficacy of this drug is currently tied to a specific patient profile: non-cirrhotic patients with moderate baseline HBsAg levels (between 100 and 3,000 IU/mL) who were already receiving stable nucleotide analogue therapy.

The distinction between a functional cure and a complete cure

Bepirovirsen provides a functional cure rather than a total eradication of the virus. A functional cure is distinguished from a complete cure by the persistence of viral genetic material within the host.

Persistence of cccDNA

Like existing nucleotide analogues, bepirovirsen does not eliminate the covalently closed circular DNA (cccDNA) that is embedded into the host's DNA. Because HBV is an rt-DNA virus, it embeds itself into the host genome, which creates a lifelong challenge for complete eradication. As noted by community discussion:

"Like the nukes, bepi doesn’t eliminate the embedded cccDNA... That's the ugly part about these rt-DNA viruses. They embed into your own DNA, causing issues for life."

Clinical limitations and population scope

While the 19% functional cure rate is a statistically significant result, its impact on global HBV mortality—estimated at 1.1 million deaths per year—remains uncertain. The current trial data is limited by the specific demographics of the enrolled participants.

Exclusions of high-risk patients

The trial specifically excluded patients with cirrhosis and those with high antigen loads. Because HBV-related deaths are primarily driven by hepatocellular carcinoma and cirrhosis, the drug's ability to reduce overall mortality depends on future trials involving populations with more advanced disease and higher viral loads.

Perspectives on the HBV treatment landscape

The development of bepirovirsen occurs alongside existing preventative measures and potential future generic access.

Preventative vs. Curative measures

There has been an HBV vaccine available for approximately 40 years, which serves as a primary preventative measure. However, a vaccine does not treat an existing infection, necessitating the development of curative drugs like bepirovirsen for those already infected.

Accessibility and Biosimilars

There is anticipation that pharmaceutical companies, particularly in India, may produce biosimilars of such treatments. This would potentially lower costs and increase accessibility for patients in Africa and Asia, where the burden of HBV is high.